MedPath

Halia Therapeutics, Inc.

Halia Therapeutics, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2017-01-01
Employees
11
Market Cap
-
Website
http://www.haliatherapeutics.com

Clinical Trials

4

Active:1
Completed:3

Trial Phases

3 Phases

Phase 1:2
Phase 2:1
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (50.0%)
Not Applicable
1 (25.0%)
Phase 2
1 (25.0%)

HT-6184 in Subjects With MDS

Not Applicable
Active, not recruiting
Conditions
Myelodysplastic Syndrome
Anemia in Myelodysplastic Syndromes
Interventions
First Posted Date
2025-07-04
Last Posted Date
2025-07-14
Lead Sponsor
Halia Therapeutics, Inc.
Target Recruit Count
37
Registration Number
NCT07052006
Locations
🇮🇳

Nil Ratan Sircar Medical College and Hospital, Kolkata, Bengal, India

🇮🇳

Hemato Oncology Clinica Ahmedabad Pvt. Ltd. Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat, India

🇮🇳

Shalby Hospital, Ahmedabad, Gujarat, India

and more 7 locations

Study to Evaluate HT-4253 in Healthy Subjects

Phase 1
Completed
Conditions
Normal Healthy Subjects
Interventions
Drug: Placebo
First Posted Date
2024-08-05
Last Posted Date
2025-06-11
Lead Sponsor
Halia Therapeutics, Inc.
Target Recruit Count
80
Registration Number
NCT06537817
Locations
🇦🇺

CMAX Clinical Research, Adelaide, South Australia, Australia

Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction

Phase 2
Completed
Conditions
Pain
Interventions
Drug: HT-6184 Placebo
First Posted Date
2024-02-05
Last Posted Date
2025-03-30
Lead Sponsor
Halia Therapeutics, Inc.
Target Recruit Count
81
Registration Number
NCT06241742
Locations
🇺🇸

CenExel JBR, Murray, Utah, United States

Study to Evaluate HT-6184 in Healthy Subjects

Phase 1
Completed
Conditions
Normal Healthy Subjects
Interventions
Drug: HT-6184 Placebo
First Posted Date
2022-07-07
Last Posted Date
2023-08-28
Lead Sponsor
Halia Therapeutics, Inc.
Target Recruit Count
64
Registration Number
NCT05447546
Locations
🇺🇸

TKL Research, Inc., Fair Lawn, New Jersey, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.